C2b-Targeting Binding Molecule for Selective Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inhibiting complement activation in inflammatory diseases often come with the risk of increased susceptibility to infections, as they can impair the body's ability to defend against microorganisms, and existing antibodies targeting C2 have not been effective in blocking its activation.
Innovation Solution
Development of a binding molecule comprising specific immunoglobulin heavy and light chain variable regions that selectively target the C2b domain of human complement factor C2, inhibiting complement activation while preserving the alternative pathway's functionality to maintain immune defense.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If complement activation is inhibited to treat inflammatory diseases, then complement-mediated tissue damage is reduced, but susceptibility to infections increases
Solution Approach 1:
The binding molecule specifically targets the C2b domain of complement factor C2, creating a localized inhibition effect on the classical and lectin pathways while leaving the alternative pathway intact. This selective local action reduces complement-mediated tissue damage in inflammatory diseases without completely suppressing the complement system, thereby maintaining immune defense against infections
Solution Approach 2:
The invention segments the complement system inhibition by targeting only a specific component (C2b domain) rather than inhibiting the entire complement cascade. This segmentation allows differential control of complement pathways, enabling therapeutic inhibition of harmful pathways while preserving protective functions
2Object-affected harmful factors
If existing antibodies targeting C2 are used to inhibit complement activation, then complement-mediated damage is reduced, but they fail to effectively block C2 activation
Solution Approach 1:
The invention replaces existing antibody-based approaches with a novel binding molecule that has proven effectiveness in blocking C2 activation. The binding molecule comprises specifically engineered immunoglobulin heavy and light chain variable regions that target the C2b domain, providing superior blocking effectiveness compared to previously tested antibodies against C2
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The binding molecule effectively treats conditions like myasthenia gravis, haemolytic anaemia, and ischemia-reperfusion injuries by limiting complement-mediated damage without significantly increasing the risk of infections, by inhibiting the classical and lectin pathways while sparing the alternative pathway.
Implementation Method 1
a binding molecule that binds to human complement factor C2... wherein the binding molecule comprises an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The invention relates to means and methods that relate to binding molecules that bind human complement factor C2. Specific binding molecules are described with specific C2 activity inhibiting properties. Such binding molecules are useful in the treatment of symptoms of various human disease among which there is inflammatory disease, neuro-inflammatory disease or ischemia-reperfusion (I/R) injury.